A fast-dissolving CBD tablet designed for easier anxiety treatment

Quality by Design-Driven Formulation Development of Cannabidiol Orally Disintegrating Tablets.

Scientifica β€’ β€’ Highly Relevant
πŸ€–

AI Summary

This study developed cannabidiol (CBD) orally disintegrating tablets using a Quality by Design (QbD) approach. The goal was to create a patient-friendly tablet that breaks apart quickly in the mouth and could support CBD delivery for anxiety treatment. The researchers evaluated how tablet pressure and the amounts of two inactive ingredientsβ€”microcrystalline cellulose and croscarmellose sodiumβ€”affected tablet quality.

The selected formulation contained 4% CBD, or 10 mg per tablet, along with 35% microcrystalline cellulose and 1% croscarmellose sodium, and was compressed at 1400 pounds per square inch. It had a hardness of about 5 kg-force, disintegrated in 13–15 seconds, and had approximately 0.3% friability, indicating that it was both quick-dissolving and mechanically stable. Laboratory testing found CBD content and assay results between 90% and 100%, while approximately 76% dissolved within 3 hours in the test solution. The study developed and verified the tablet formulation, but it did not test whether the tablets actually reduce anxiety in patients.

πŸ’‘ Key Findings

1
A Quality by Design approach successfully produced CBD orally disintegrating tablets with the targeted quality characteristics.
High
80%
2
The optimized tablets contained 10 mg of CBD and disintegrated in 13–15 seconds, offering a potentially convenient format for users who have difficulty swallowing conventional tablets.
High
80%
3
The formulation showed approximately 0.3% friability and about 5 kg-force hardness, suggesting a balance between tablet durability and rapid disintegration.
Good
75%
4
Laboratory testing found CBD content and assay results between 90% and 100%, with approximately 76% dissolved within 3 hours in the stated test solution.
Good
75%
5
The study supports formulation feasibility, but does not provide clinical evidence that the tablets treat anxiety.
High
90%

πŸ“„ Original Abstract

The development of cannabidiol (CBD) orally disintegrating tablets (ODTs) is effective in treating anxiety in a patient-friendly manner. The application of Quality by Design (QbD) enhances the efficiency and robustness of the pharmaceutical development of CBD ODTs. The objective of this work was to develop a formulation for CBD ODTs using a QbD-driven approach. Quality target product profile, critical quality attributes, and an initial risk assessment were identified and evaluated. Subsequently, a Box-Behnken design was employed to analyze the effects of varied compression force, the quantity of microcrystalline cellulose, and the quantity of croscarmellose sodium to create a design space and control space. Results indicated that the design and control spaces produced tablets with hardness ranging from 4 to 6 kg-force, a disintegration time (DT) ≀ 30 s, and a friability ≀ 1%. All formulations contained 4% CBD (or 10 mg per tablet). The optimal formulation consisted of 35% microcrystalline cellulose and 1% croscarmellose sodium and was compressed at 1400 pounds per square inch. This formulation exhibited a hardness of approximately 5 kg-force, a DT of 13-15 s, and a friability of approximately 0.3%. Verification data confirmed the accuracy of the predictions made by computer software. The content uniformity and assay determined using validated high-performance liquid chromatography ranged between 90% and 100%. CBD was released from the CBD ODT in 1% sodium lauryl sulfate solution, with approximately 76% dissolved within 3 h in the dissolution study. In conclusion, the QbD-driven approach successfully facilitated the formulation development of CBD ODTs with the desired properties for the treatment of anxiety in a patient-friendly manner.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.